1-(1,1,1,3,3,3-Hexafluoropropan-2-Yloxy)-3-(2-Nitroimidazol-1-Yl)Propan-2-Ol
CAS : 104290-39-3
Ref. 3D-FH99983
Taille indéfinie | Arrêté |
Informations sur le produit
- 1H-Imidazole-1-ethanol, 2-nitro-alpha-((2,2,2-trifluoro-1-(trifluoromethyl)ethoxy)methyl)-
- 1-[(1,1,1,3,3,3-hexafluoropropan-2-yl)oxy]-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol
1-(1,1,1,3,3,3-Hexafluoropropan-2-Yloxy)-3-(2-Nitroimidazol-1-Yl)Propan-2-Ol (HFPO) is a novel prodrug that is activated by hypoxia. HFPO has been shown to be effective in inhibiting tumor growth in mouse models of subcutaneous tumors. The drug binds to the hypoxic tumor cells and inhibits DNA synthesis. This leads to cell death by inhibiting protein synthesis and cell division. HFPO can also be used for the treatment of radiation therapy for solid tumours such as breast cancer and prostate cancer.